Sandoz’ Neulasta Biosimilar Filing Joins Another Pending At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Novartis drug unit said the biosimilar pegfilgrastim application was accepted by FDA, positioning the 351(k) filing for action in mid-2016.
You may also be interested in...
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.